D
Overview
Double Blind Bio offers a subscription SaaS platform that uses AI to streamline clinical trial operations for community research sites and sponsors. Its core product features Debby, an AI assistant that automates site administrative tasks and helps match sites with suitable trials. The platform includes AI-driven trial discovery, automated feasibility analysis, and personalized sponsor outreach, backed by centralized site data and analytics. The goal is to speed up study startup and increase trial opportunities to accelerate the development of new medical treatments.
Work here?Claim your company
Simplify's Take
What believers are saying
- August 2026 funding reportedly reached $7.0 million, extending runway for hiring.
- The company claims 400-plus clinical research sites are already using the platform.
- Clinical operations are shifting toward agentic AI, matching Double Blind Bio's product direction.
What critics are saying
- Florence Healthcare already serves 65,000 sites and 600 sponsors, crushing distribution.
- Veeva eSource ships in late 2026, squeezing study-startup and data-workflow budgets.
- Double Blind Bio still looks early-stage; a misfire on usage kills product-market fit.
What makes Double Blind Bio unique
- Double Blind Bio launched Debby to automate site and sponsor workflows in 2026.
- Founders Shruti Tibrewala and Dave Hughes combine life sciences and enterprise software experience.
- Their platform targets community research sites, not only sponsors, widening adoption channels.
Help us improve and share your feedback! Did you find this helpful?